Zura Bio Limited
Zura Bio Limited, a clinical-stage biotechnology company, develops medicines for immune and inflammatory disorders in the United States. The company develops Tibulizumab, an immunoglobulin G-single-chain variable fragment bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes interleukin (IL)-17A and B-cell activating factor, which is in Phase 2 … Read more
Zura Bio Limited (94E) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.130x
Based on the latest financial reports, Zura Bio Limited (94E) has a cash flow conversion efficiency ratio of -0.130x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-15.44 Million) by net assets (€118.44 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Zura Bio Limited - Cash Flow Conversion Efficiency Trend (2021–2024)
This chart illustrates how Zura Bio Limited's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Zura Bio Limited Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Zura Bio Limited ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Shanghai Huide Science & Technology Co Ltd
SHG:603192
|
0.044x |
|
ACG Metals Limited
PINK:ACGAF
|
N/A |
|
Caisse Régionale de Crédit Agricole Mutuel Sud Rhône Alpes
LSE:0O3Q
|
N/A |
|
Hunan Tyen Machinery Co Ltd B
SHG:900946
|
0.006x |
|
Shanghai Menon Animal Nutrition Technology Co. Ltd.
SHE:301156
|
0.051x |
|
Audinate Group Ltd
AU:AD8
|
0.038x |
|
91App Inc
TWO:6741
|
0.010x |
|
Copper 360 Ltd
JSE:CPR
|
N/A |
Annual Cash Flow Conversion Efficiency for Zura Bio Limited (2021–2024)
The table below shows the annual cash flow conversion efficiency of Zura Bio Limited from 2021 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | €160.02 Million | €-28.08 Million | -0.175x | +7.28% |
| 2023-12-31 | €79.55 Million | €-15.05 Million | -0.189x | -2138.44% |
| 2022-12-31 | €126.69 Million | €-1.07 Million | -0.008x | +96.40% |
| 2021-12-31 | €4.68 Million | €-1.10 Million | -0.235x | -- |